-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On December 10th, Suoyuan Bio and QIAGEN jointly announced that the two parties will cooperate on a global scale to develop blood-based companion diagnostics (CDx) products to detect Suoyuan Bio’s newly discovered pharmacogenomic biomarkers.
DB102 is a small-molecule serine/threonine kinase inhibitor with "first-in-class" potential acquired by Suoyuan Biotech from Eli Lilly and Company, which acts on PKCβ, PI3K and AKT and other tumor fields Key tumor targets
(The original text has been deleted)